We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Patients rely on drug products to help protect their health and prevent complications. Pharmaceutical manufacturers rely on a drug product’s primary packaging container and delivery system to maintain the drug quality and ensure that their drug is delivered safely and effectively. But like any drug product, there are risks associated with containment and delivery systems. On February 23, West hosted a training event, “Understanding Risks Associated with Containment and Delivery Systems Across the Biologic Product Lifecycle from Formulation to Commercialization” a joint presentation from West, Patheon and the National Institute for Bioprocessing Research and Training (NIBRT).
The purpose of this symposium was to bring about awareness of the important characteristics of materials, processes and components of containment and delivery systems that protect and deliver biologic products and ensure manufacturability. This one-day event provided the opportunity to understand the role of containment and delivery systems, as well as hear more about unmet patient needs. A discussion forum on how alliances can be built to facilitate speed to market, enabling comprehensive product and process understanding, was a key outcome of the event.
West provided insight on:
The role of containment and delivery systems
Visible and sub-visible particulate
Risks for biologic de-stabilization or degradation when in contact with various materials
Assessment of extractables and potential for leachables
Assurance of sterility through integral containment systems
NIBRT, a global center of excellence for training and research, specializes in training bioprocessing professionals and those interested in container closure systems that protect sensitive biologic drug products and delivery systems. West initiated a partnership with NIBRT in 2016 as part of the European Emerging biotech strategy and has since evolved to a broader collaboration to conduct leading research on the development and manufacturing of innovative biopharmaceuticals. Patheon, an end-to-end supply chain provider for pharmaceutical and biopharmaceutical companies, presented options for fill-finish operations and tech transfer verification.
The February event had 42 attendees, representing 25 companies--including mature biologics and emerging biotech firms, primarily from the UK and Ireland. This allowed West to gain valuable insight regarding the needs of customers in Europe.
The event was a great way for West’s technical experts to share their insights, and at the same time, gain insight from customers who are developing and manufacturing advanced biologics drug products. The key learnings that came from the NIBRT event will help West overcome challenges and continue to set the highest standards in this marketplace.
Where will West be next? Check out our Events page for more information.
In order to ensure the best quality drug product and optimal patient outcomes, it’s important for drug manufacturers to foster a collaborative effort with their packaging suppliers from the beginning – and that means starting with the patient in mind. Understanding patient needs and how that drug will be delivered, whether through one of West’s delivery devices or some other device, will help determine the needs within the West manufacturing process.
We are excited to share that West has been recognized for "Best Bioprocessing Supplier: Fill-Finish" at the Asia-Pacific Bioprocessing Excellence Awards 2022, the India Biologics and Vaccines Outstanding Industry Awards 2022, and the Korea Bioprocessing Excellence Awards 2022.
At West, one of our core values is passion for customers. Their success is ultimately our success. Understanding our customers’ unique challenges and focus areas, ultimately helps us to better provide solutions for their needs. Recently, the West China Commercial Team visited one of our major local customers, Wuxi Biologics, and hosted its first large-scale on-site customer event, “Innovation Day.” As one of our major local customers, Wuxi Biologics is a leading company in China’s prosperous biopharmaceutical industry. The event drew over 140 participants and expanded our strategic collaboration, which will help us further support Wuxi Biologics with their specific drug development needs.
When you think of injectable medication, a classic image may include a set of hands holding both a vial and a syringe to withdraw medication prior to injection. Advances in both drug products and self-injection options – including auto-injectors, pens and other self-injection devices – have helped to draw a new picture for injectable delivery.<br />
The number of biologic drug products marketed with an injection device has approximately quadrupled over the last decade. The growth in these drug therapies has been driven by several factors including new, self-administered therapies for chronic conditions such as rheumatoid arthritis and autoimmune diseases. In addition, injectable therapy is now being considered as a treatment for more conditions, including asthma and cholesterol problems.
English
Chinese
